0001615774-18-001760.txt : 20180309
0001615774-18-001760.hdr.sgml : 20180309
20180309160141
ACCESSION NUMBER: 0001615774-18-001760
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180307
FILED AS OF DATE: 20180309
DATE AS OF CHANGE: 20180309
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vivo Capital VIII, LLC
CENTRAL INDEX KEY: 0001618789
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37411
FILM NUMBER: 18680050
BUSINESS ADDRESS:
STREET 1: 505 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: 650 688 0822
MAIL ADDRESS:
STREET 1: 505 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CA
ZIP: 94301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BioPharmX Corp
CENTRAL INDEX KEY: 0001504167
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 593843182
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0131
BUSINESS ADDRESS:
STREET 1: 1505 ADAMS DRIVE, SUITE D
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650-889-5020
MAIL ADDRESS:
STREET 1: 1505 ADAMS DRIVE, SUITE D
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER COMPANY:
FORMER CONFORMED NAME: THOMPSON DESIGNS INC
DATE OF NAME CHANGE: 20101022
4
1
s109293_form4.xml
4
X0306
4
2018-03-07
0
0001504167
BioPharmX Corp
BPMX
0001618789
Vivo Capital VIII, LLC
505 HAMILTON AVENUE, SUITE 207
PALO ALTO
CA
94301
0
0
1
0
Common Stock
2018-03-07
4
S
0
2000000
0.36
D
16128515
I
See Footnote
These shares are owned directly by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., which are the record owners of these shares. Vivo Capital VIII, LLC is the general partner of both Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. and may be deemed to beneficially own such shares. The voting members of Vivo Capital VIII, LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu, and Shan Fu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
/s/ Albert Cha, Managing Member of Vivo Capital VIII, LLC
2018-03-09